Stock Events

Stock Events

Wuxi Biologics (Cayman) 

€5.46
71
-€0.07-1.21%Friday 07:05

Statistics

Day High
5.46
Day Low
5.46
52W High
6.56
52W Low
3.27
Volume
0
Avg. Volume
609
Mkt Cap
22.61B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Aug 25Expected
Q4 2025
Q2 2026
0.06
0.06
0.07
0.08
Expected EPS
0.0567268515
Actual EPS
0.07311460859999999

Financials

22.51%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
2.62BRevenue
590.02MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1FW2.MU. It's not an investment recommendation.
Apple
13
AAPL
Microsoft
12
MSFT
NVIDIA
12
NVDA
Tesla
10
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sartorius
SARTF
Mkt Cap14.69B
Sartorius Stedim Biotech is a supplier of equipment and services for biopharmaceutical manufacturing, competing in the bioprocessing space with Wuxi Biologics.
Charles River Laboratories International
CRL
Mkt Cap17.16B
Charles River Laboratories offers a broad range of services to support the pharmaceutical and biotech industries, including biologics testing services.
Thermo Fisher Scientific
TMO
Mkt Cap257.71B
Thermo Fisher Scientific provides bioproduction and bioprocessing products and services, competing with Wuxi Biologics in the supply of critical biomanufacturing technologies.
Danaher
DHR
Mkt Cap163.25B
Danaher, through its subsidiaries like Cytiva, competes in the bioprocessing space by providing technologies and services for biomanufacturing.
Bio-Rad Laboratories
BIO
Mkt Cap9.95B
Bio-Rad Laboratories offers products and services in the field of life science research and clinical diagnostics, competing in the biologics tools and services market.
IQVIA
IQV
Mkt Cap44.06B
IQVIA provides advanced analytics, technology solutions, and contract research services to the life sciences industry, competing in the broader biopharmaceutical services market.
Pfizer
PFE
Mkt Cap173.95B
Pfizer, through its contract manufacturing organization Pfizer CentreOne, competes in the biologics manufacturing and development services sector.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences, while primarily a biopharmaceutical company, competes for resources, talent, and market share in the biologics sector, particularly in areas of overlapping therapeutic interest.

About

Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
Show More
CEO
Zhisheng Chen
Employees
14705
Country
China
ISIN
KYG970081173
WKN
000A2QJCN

Listings

MU
DE
1FW.MU
STU
DE
1FW1.STU
STU
DE
1FW2.STU
MU
DE
1FW1.MU

0 Comments

Share your thoughts

FAQs

What is Wuxi Biologics (Cayman) stock price today?▼
The current price of 1FW2.MU is €5.46 EUR — it has decreased by -1.21% in the past 24 hours. Watch Wuxi Biologics (Cayman) stock price performance more closely on the chart.
What is Wuxi Biologics (Cayman) stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Wuxi Biologics (Cayman) stocks are traded under the ticker 1FW2.MU.
Is Wuxi Biologics (Cayman) stock price growing?▼
1FW2.MU stock has risen by +7.5% compared to the previous week, the month change is a -12.24% fall, over the last year Wuxi Biologics (Cayman) has showed a +44.64% increase.
What is Wuxi Biologics (Cayman) market cap?▼
Today Wuxi Biologics (Cayman) has the market capitalization of 22.61B
When is the next Wuxi Biologics (Cayman) earnings date?▼
Wuxi Biologics (Cayman) is going to release the next earnings report on March 23, 2027.
What were Wuxi Biologics (Cayman) earnings last quarter?▼
1FW2.MU earnings for the last quarter are 0.07 EUR per share, whereas the estimation was 0.06 EUR resulting in a +28.89% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Wuxi Biologics (Cayman) revenue for the last year?▼
Wuxi Biologics (Cayman) revenue for the last year amounts to 2.62B EUR.
What is Wuxi Biologics (Cayman) net income for the last year?▼
1FW2.MU net income for the last year is 590.02M EUR.
How many employees does Wuxi Biologics (Cayman) have?▼
As of November 8, 2026, the company has 14,705 employees.
In which sector is Wuxi Biologics (Cayman) located?▼
Wuxi Biologics (Cayman) operates in the Health & Wellness sector.
When did Wuxi Biologics (Cayman) complete a stock split?▼
The last stock split for Wuxi Biologics (Cayman) was on December 10, 2020 with a ratio of 3:1.
Where is Wuxi Biologics (Cayman) headquartered?▼
Wuxi Biologics (Cayman) is headquartered in Wuxi, China.